Navigation Links
Savient Closes Sale of $230 Million in Convertible Senior Notes
Date:2/4/2011

e SEC Web site at www.sec.gov.  Alternatively, copies of the prospectus meeting the requirements of Section 10 of the Securities Act of 1933 may be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717; Telephone (631) 254-1735.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase), which was approved by the FDA on September 14, 2010 for the treatment of chronic gout in adult patients refractory to conventional therapy.

Safe Harbor Statement

This press release contains forward-looking statements, including statements about future business prospects, KRYSTEXXA™ and the offering, that are intended to be covered by the safe harbor provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934.  Any statements that are not statements of historical fact (including statements containing the words "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "may," "predict," "will," and "would," and similar expressions) should be considered to be forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated in any forward-looking statements made by Savient, including the factors described in Savient's Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, which has been filed with the Securities and Exchange Commission.

SVNT - I


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. Savient Provides Update on Pegloticase BLA
3. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
4. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
6. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
7. Savient Provides Update on KRYSTEXXA(TM) BLA Resubmission Activities
8. Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010
9. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
10. Savient Resubmits Biologics License Application for KRYSTEXXA(TM) (pegloticase) for the Treatment of Chronic Gout in Patients Refractory to Conventional Therapy
11. Savient Pharmaceuticals To Hold First Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Today, Wall Street Reports ... GILD ), Health Management Associates Inc. (NYSE: ... ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ), and Trius ... free of charge - including full price targets, industry analysis ... Gilead Sciences, Inc. Research Report On June 7, ...
(Date:6/18/2013)... SALT LAKE CITY , June 18, 2013 ... registry-based informatics products for healthcare and life sciences ... U.S. General Services Administration (GSA) IT Schedule 70 ... is now certified to provide innovative IT solutions ... levels. In accordance with this contract, Remedy has ...
(Date:6/18/2013)... 2013 Apama Medical, a privately held ... next-generation atrial fibrillation technologies, today announced the issuance ... Patent and Trademark Office (USPTO), titled "Low Profile ... for use on expandable structures such as balloons ... "We are grateful to the NSF ...
Breaking Medicine Technology:Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4
... announced that data,presented recently at the 17th Annual ... that the Genous Bio-engineered R,stent has better outcomes ... Federico Piscione, M.D., the study,s principal,investigator and a ... of Cardiology, Department of Clinical Medicine and Cardiovascular,Sciences, ...
... Results are basis for CTI,s Marketing Authorization Application currently ... under ... Inc. (CTI),(Nasdaq: CTIC ; MTA) today announced the publication of ... gemcitabine or vinorelbine for the treatment of PS 2,(performance status 2) ...
Cached Medicine Technology:Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 2Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 2Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 3Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 4Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology 5
(Date:6/18/2013)... June 18, 2013 As obesity rates sky ... need for surgical equipment during childbirth comes as no shock. ... within the mother when she is unable to do so ... are associated with higher rates of complication for both the ... harmful to the mother and child, forceps births add to ...
(Date:6/18/2013)... WA (PRWEB) June 18, 2013 SEATTLE, ... Townsend Farms of Fairview, Oregon, claiming he fell ill ... frozen berry and pomegranate seed blend. The complaint ... 13-2-05597-8) by Marler Clark, the Seattle-based law firm that ... .[1] , According to the complaint, Brian Brothers consumed ...
(Date:6/18/2013)... The Drug Delivery Partnering Terms and Agreements ... drug delivery partnering deals and agreements entered into by ... provides a detailed understanding and analysis of how and ... of deals are discovery or development stage whereby the ... license the license drug delivery technology. These deals tend ...
(Date:6/18/2013)... The Temp1000IS temperature data logger ... can be used to automatically record temperatures between -20 ... Temp1000IS comes with the serial number and device name ... (sold separately) docking station and can be placed directly ... removal of end-caps to download data. The small size ...
(Date:6/18/2013)... Parker Waichman LLP , a ... victims injured by defective medical devices, reports that the ... bone graft products are now available. Published this week ... two studies serve up two key findings: There is ... and the traditional bone graft; and there is “substantial ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3
... Reinberg HealthDay Reporter , WEDNESDAY, May 25 ... a "polypill," appears to cut users, odds for heart ... study finds. The pill combines two blood pressure-lowering ... designed to make all these heart-protecting drugs easy to ...
... 25, 2011) The cost of cancer care is threatening ... but at staggering costs. This coupled with aging baby boomers ... billion annually on cancer care by the year 2020. This ... maintain or improve the quality of care while saving money ...
... CA (May 26, 2011) Precision tinted lenses have ... poor readers, and are increasingly used for migraine sufferers, ... been unclear. Now research published in the journal ... imaging (fMRI) for the first time to suggest a ...
... NY, May 26, 2011Young adults ages 19-29 are struggling to ... other age group, demonstrating the need for Affordable Care Act ... and make it more affordable, according to a new Commonwealth ... of young adults couldn,t afford the care they needed, meaning ...
... 2011 UT Southwestern Medical Center researchers are engaging the ... component in red wine and grapes could help reduce the ... recruit about two dozen professional boxers to take the neuroprotective ... damage to the brain after impact and helps restore subtle ...
... bats and dolphins echolocate, emitting bursts of sounds and then ... What is less well-known is that people can echolocate too. ... make clicks with their mouths and to use the returning ... these individuals are so adept at echolocation that they can ...
Cached Medicine News:Health News:Daily Four-Drug Combo Pill Halves Heart Disease Risk: Study 2Health News:Daily Four-Drug Combo Pill Halves Heart Disease Risk: Study 3Health News:Oncologists hold key to curbing cancer costs 2Health News:Oncologists hold key to curbing cancer costs 3Health News:Tinted specs offer real migraine relief, says fMRI study 2Health News:Tinted specs offer real migraine relief, says fMRI study 3Health News:Health reform essential to young adults: Nearly half can't afford needed health care 2Health News:Health reform essential to young adults: Nearly half can't afford needed health care 3Health News:Health reform essential to young adults: Nearly half can't afford needed health care 4Health News:Researchers evaluate red wine compound for treating concussions in pro boxers 2Health News:'I can hear a building over there' 2
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The BD Vacutainer® One Use Holder is a quality, low-cost single use holder that can help customers comply with OSHA regulations (Safety and Health Information Bulletin 10-15-03)...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Inquire...
Medicine Products: